Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Champions Oncology (CSBR) Accumulated Expenses (2016 - 2026)

Champions Oncology (CSBR) has 15 years of Accumulated Expenses data on record, last reported at $2.2 million in Q4 2025.

  • For Q4 2025, Accumulated Expenses fell 2.1% year-over-year to $2.2 million; the TTM value through Oct 2025 reached $2.2 million, down 2.1%, while the annual FY2025 figure was $2.6 million, 18.33% up from the prior year.
  • Accumulated Expenses reached $2.2 million in Q4 2025 per CSBR's latest filing, up from $1.8 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $2.6 million in Q2 2025 and bottomed at $1.7 million in Q4 2022.
  • Average Accumulated Expenses over 5 years is $2.1 million, with a median of $2.1 million recorded in 2024.
  • The widest YoY moves for Accumulated Expenses: up 125.66% in 2021, down 18.01% in 2021.
  • A 5-year view of Accumulated Expenses shows it stood at $1.9 million in 2021, then dropped by 12.61% to $1.7 million in 2022, then grew by 21.14% to $2.0 million in 2023, then increased by 10.48% to $2.2 million in 2024, then fell by 2.1% to $2.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Expenses were $2.2 million in Q4 2025, $1.8 million in Q3 2025, and $2.6 million in Q2 2025.